Livdelzi accepted in Scotland for treatment of PBC
Gilead Sciences' Livdelzi (seladelpar) approved by the Scottish Medicines Consortium for NHS use in Scotland to treat primary biliary cholangitis (PBC). The drug is for adults with PBC, either in combination with UDCA or as monotherapy. Around 2,000 people in Scotland live with PBC, a rare autoimmune liver disease. The decision is based on evidence from the global phase 3 RESPONSE trial. Livdelzi is already available in England, Wales, and Northern Ireland.
How this was made
The 30-second read
Why it matters
The decision reflects regulatory confidence and may set a precedent for further European roll‑outs.
Market read
Regulatory approval could modestly boost Gilead's stock and signals progress in its liver‑disease franchise.
What to watch
Reimbursement negotiations and competition from existing PBC therapies could limit revenue.
Background
Gilead's seladelpar was previously approved in England, Wales and Northern Ireland after NICE guidance; this extends its availability to Scotland.
Ticker impact
Gilead Sciences received SMC acceptance for its drug Livdelzi (seladelpar) for PBC treatment in Scotland.
Modest upside as investors price in new market access.
The approval adds a new indication in a niche market; impact depends on uptake and reimbursement.
Market effects
Strengthens the liver‑disease therapeutic segment and may boost peers with similar pipelines.
Adds a new treatment option for NHS Scotland, potentially influencing UK healthcare spend.
Limited to niche PBC market but highlights Gilead's expanding liver‑disease portfolio.
Counterpoint
The market may have already priced in UK expansion; uptake could be slower than expected.
Key entities
- CompanyGilead Sciences
Pharmaceutical company developing Livdelzi (seladelpar).
- RegulatorScottish Medicines Consortium
Body that accepted the drug for NHS Scotland use.
